Predicting Prognosis of Early-Stage Non-Small Cell Lung Cancer Using the GeneFx® Lung Signature

Use of adjuvant chemotherapy remains a complex decision in the treatment of early stage non-small cell lung cancer (NSCLC), with risk of recurrence being the primary indicator (i.e. adjuvant chemotherapy is considered for patients at high risk of recurrence but may not be beneficial for patients at...

Descripción completa

Detalles Bibliográficos
Autores principales: Der, Sandy, Zhu, Chang-Qi, Brower, Stacey, Uihlein, Arlette
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2015
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4630007/
https://www.ncbi.nlm.nih.gov/pubmed/26558161
http://dx.doi.org/10.1371/currents.eogt.49eb4408c48237b8a8d4ed2060951083

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4630007/
https://www.ncbi.nlm.nih.gov/pubmed/26558161
http://dx.doi.org/10.1371/currents.eogt.49eb4408c48237b8a8d4ed2060951083

Ejemplares similares